NCT00195572View on ClinicalTrials.gov

Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Gastric Cancer
Interventions
DRUG

Isovorin

DRUG

TS-1

Trial Locations (43)

123-0855

Adachi-ku, Tokyo

446-8602

Anjo

030-8553

Aomori

260-8607

Chiba

260-8717

Chiba

818-8502

Chikushino-shi

812-8582

Fukuoka

437-0061

Fukuroi-shi

629-0392

Funai-gun

730-8619

Hiroshima

734-8551

Hiroshima

290-0003

Ichihara-shi

224-8503

Kanagawa

920-8641

Kanazawa

292-8535

Kisaradu-shi

362-0806

Kitaadachi-gun

135-8577

Koto-ku, Tokyo

602-8566

Kyoto

033-0001

Misawa-shi

020-8505

Morioka

852-8501

Nagasaki

458-0037

Nagoya

464-8681

Nagoya

537-8511

Osaka

545-8585

Osaka

856-8562

Ōmura

840-8571

Saga

228-8520

Sagamiharashi

064-0923

Sapparo City

003-8585

Sapporo

060-0001

Sapporo

060-8543

Sapporo

857-8511

Sasebo-shi

983-8512

Sendai

983-8520

Sendai

432-8580

Shizuka

420-8527

Shizuoka

420-8623

Sizuoka-shi

569-8666

Takatuki-si

300-0053

Tsuchiura-shi

305-8576

Tsukuba

611-0042

Uji-shi

990-2292

Yamagata

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00195572 - Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer | Biotech Hunter | Biotech Hunter